Cannabigerol-Based Nanoparticles Show Promising Therapeutic Potential

Strategic Insights -

Researchers at the University of Milan have discovered a new application for cannabigerol (CBG), a non-psychoactive phytocannabinoid, in the development of nanoparticles for targeted cancer therapy. CBG-based nanoparticles have shown to exhibit antiproliferative activity, indicating their potential as a versatile nanomedicine platform for cancer treatment.

Key Takeaways:

  • The researchers conjugated CBG with tubulin-targeting drugs, such as * * N* * -desacetylthiocolchicine, paclitaxel, and camptothecin, using sebacic acid and 4,4'-dithiodibutyric acid as linkers, to create nanoparticles.
  • The nanoparticles were characterized by their stability and size, with hydrodynamic diameters ranging from 120 to 140 nm.
  • The study demonstrated that CBG-based nanoparticles can enhance anticancer activity by targeting cancer cells.
  • The researchers highlight the importance of linker chemistry in modulating therapeutic efficacy.
  • The findings support the development of multifunctional drug delivery systems for targeted cancer therapy.

Statistics:

  • 17(5):636 is the issue and page number of the research publication in Pharmaceutics.
  • The research was published on June 10, 2025.
  • The study involved a team of 12 researchers from the University of Milan.
  • CBG-based nanoparticles were characterized by their stability and size, with hydrodynamic diameters ranging from 120 to 140 nm.

Sources:

  • Amenta, A., et al. (2025). Self-Assembled Cannabigerol-Based Nanoparticles: Design, Synthesis, and Antiproliferative Activity. Pharmaceutics, 17(5), 636. (https://doi-org.sdpl.idm.oclc.org/10.3390/pharmaceutics17050636)
  • NewsRx. Recent Studies from University of Milan Add New Data to Cannabigerol (Self-Assembled Cannabigerol-Based Nanoparticles: Design, Synthesis, and Antiproliferative Activity). Cancer Weekly. June 10, 2025; p 1119.